RetroVirox is the only CRO exclusively focused on the antiviral field. RetroVirox has a large menu of validated antiviral services, including assays to evaluate small-molecule antivirals, antibodies and vaccines against many human viruses such as coronavirus, HIV, influenza, RSV, Dengue, Zika, CMV, rhinovirus, and other infectious agents. RetroVirox offers also neutralization assays against highly pathogenic viruses using pseudoviruses (COVID-19, Ebola, Lassa, and pandemic influenza). The company has optimized assays with heterologous pseudovirus carrying the glycoproteins of highly pathogenic viruses. The company also evaluates the titers of antisera from animals and humans against adeno-associated vectors and viruses used in gene therapy approaches.

Since 2010, RetroVirox has also provided customized services to companies worldwide, including optimization and validation of novel antiviral assays, tailored studies to understand the mechanism of action of antiviral agents, and production and characterization of viruses for use in preclinical studies. RetroVirox has broad expertise in high throughput screening (HTS) for antiviral targets, and has successfully completed the screening of thousands of small-molecules in multiple HTS campaigns utilizing live infectious viruses. The company is headquartered in San Diego, California, and has provided services to Biotechnology and Pharmaceutical companies in more than 20 countries.